Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into effect until 2028.

HealthDay News — Fifteen prescription medications, including Botox and the diabetes drug Trulicity, will be the focus of ...

The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations.

The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...

Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower ...

List includes medications for diabetes, cancer, arthritis, and more ...

The 15 drugs selected for negotiation include Eli Lilly’s breast-cancer drug Verzenio.

The Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those medications compared with recent annual spending, or about $8.5 billion in ...

(The Center Square) – Negotiated lower Medicare costs for 10 popular prescription drugs went into effect Thursday. How much those savings will be passed on to Medicare Part D and applicable Advantage ...

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...